Novartis AG (NVS)


NYSE - NYSE Real Time Price. Currency in USD
79.34-0.30 (-0.38%)
At close: 4:02 PM EDT

79.50 0.16 (0.20%)
After hours: 6:29 PM EDT

People also watch:
GSKSNYAZNLLYABT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open79.52
Prev Close79.64
Bid0.00 x
Ask0.00 x
Day's Range79.28 - 79.65
52wk Range69.90 - 98.95
1y Target EstN/A
Market Cap188.93B
P/E Ratio (ttm)28.33
Beta0.64
Volume789,659
Avg Vol (3m)1,467,157
Dividend & Yield2.72 (3.43%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Associated Press4 hours ago

    Novartis wins US OK for biosimilar version of Amgen's Enbrel

    U.S. regulators on Tuesday approved the first lower-cost version of Enbrel, a blockbuster anti-inflammatory drug from Amgen that is among the top-selling drugs in the world.

  • Reuters5 hours ago

    U.S. FDA approves Novartis biosimilar to Amgen's Enbrel

    The U.S. Food and Drug Administration on Tuesday approved Novartis AG's biosimilar version of Amgen Inc's arthritis drug Enbrel. The FDA approved the drug, Erelzi, known also as etanercept-szzs, for multiple inflammatory conditions including rheumatoid arthritis and plaque psoriasis, a skin condition. The agency approved the drug as a biosimilar, meaning there is no clinically meaningful differences between Erelzi and Enbrel.

  • Here’s What’s Important With The Novartis AG (ADR) (NVS) MS Data
    Insider Monkeyyesterday

    Here’s What’s Important With The Novartis AG (ADR) (NVS) MS Data

    Novartis AG (ADR) (NYSE:NVS) just put out data from its multiple sclerosis (MS) trial, and it looks as if the company is winning the race to bring a drug to market that offers a solution for patients with secondary progressive MS (SPMS), a severe form of the condition. Biogen Inc (NASDAQ:BIIB) is also working on […]